CB Therapeutics

Executive Summary

CB Therapeutics is a San Diego-based synthetic biology company leveraging yeast-based precision fermentation to produce high-value compounds for pharmaceuticals, food, and beverage industries. Founded in 2015, the company focuses on psychedelic therapeutics, cannabinoids, and novel food ingredients, operating as a B2B supplier and development partner. Its proprietary platform enables scalable, cost-effective production of complex molecules that are traditionally difficult to synthesize or extract from natural sources. With growing demand for sustainable and consistent supply of psychedelic APIs (e.g., psilocybin) and rare cannabinoids, CB Therapeutics is well-positioned to capture market share as regulations evolve and commercial applications expand. The company’s technology also addresses the need for novel, non-psychoactive cannabinoids in functional foods and beverages, targeting the multi-billion-dollar wellness market. Despite limited public financial data, CB Therapeutics’ early entry into the precision fermentation space and its focus on high-growth sectors suggest significant upside potential as the bio-manufacturing industry matures.

Upcoming Catalysts (preview)

• Q3 2026Announcement of a strategic partnership with a major pharmaceutical company for psilocybin or other psychedelic API supply50% success
• Q4 2026Launch of a novel cannabinoid ingredient (e.g., CBG or THCV) for the functional food and beverage market60% success
• Q2 2026Closing of a Series B funding round to scale production capacity and expand R&D70% success